MedPath

Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension

Phase 4
Completed
Conditions
Prolonged Second Stage of Labor
Interventions
Registration Number
NCT02265965
Lead Sponsor
University of California, San Francisco
Brief Summary

Randomized controlled clinical trial of IV nitroglycerin at cesarean delivery for second stage arrest of descent to prevent or uterine extension at the hysterectomy site.

Detailed Description

Intravenous nitroglycerin resulting in uterine relaxation has been standardly utilized for various obstetrics conditions, e.g. breech extraction of second twin in vaginal deliveries, uterine relaxation after tachysystole in labor, prior to external cephalic version, and during difficult fetal extraction during cesarean delivery for arrest of descent in labor. Currently the use of nitroglycerin is at equipoise in obstetrics for difficult cesarean delivery after second stage arrest in labor. The clinical trial will randomize women who undergo cesarean delivery for second stage arrest in labor to receive IV nitroglycerin vs saline at the time of hysterotomy. The primary outcomes will be maternal: uterine extension, blood loss, total fetal extraction time, surgical time; neonatal: cord gases at delivery, apgar scores, admission to neonatal intensive care unit.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
18
Inclusion Criteria

women 37weeks or greater gestation diagnosed with second stage arrest of descent undergoing cesarean delivery -

Exclusion Criteria

elective, active phase arrest cesarean delivery, successful operative vaginal delivery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intravenous Nitroglycerinintravenous nitroglycerinSubjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
Primary Outcome Measures
NameTimeMethod
Number of Participants With Uterine Extension of HysterotomyDuring cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Obstetrician determined whether the subject had an uterine extension.

Umbilical Artery Blood pHAt time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Measure of umbilical artery blood pH

Number of Participants With Deliveries After Which Neonate is Admitted to NICUAfter cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest
Number of Participants With Deliveries in Which Cord Blood Base Deficit is More Negative Than or Equal to Negative 12At time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

A cord blood base deficit more negative than negative 12 is abnormal and a sign of metabolic acidosis.

APGAR at 5 MinutesImmediately after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

The APGAR scale is determined by evaluating the newborn baby on five simple criteria -- Appearance, Pulse, Grimace, Activity, Respiration -- on a scale from zero to two, then summing up the five values thus obtained. The resulting APGAR score ranges from zero to 10. Zero is the worst possible score and 10 is the highest possible score.

Secondary Outcome Measures
NameTimeMethod
Fetal Extraction Time in SecondsAt time of cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Time from uterine incision to delivery (body of neonate fully extracted from uterus)

Total Operative Time in MinutesAfter cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Time from uterine incision to out of room

Surgical Blood LossDuring and after cesarean delivery, estimated to be within 4 hours after diagnosis of second stage arrest

Total blood loss will be measured

Trial Locations

Locations (1)

University California San Francisco-Labor and Delivery

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath